Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

Immune evasion in ovarian tumors involves a complex array of immune suppressive factors and cells that effectively halt the generation and clonal expansion of antitumor immunity. Genetic changes ...

Now, as a biochemist at the University of Notre Dame, Stack and her team collaborate with other scientists to investigate the processes and factors that contribute to ovarian cancer metastasis in the ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...

Additionally, mice with ovarian cancer treated with ERNA-101 exhibited ... potent pro-inflammatory factors directly to the tumor microenvironment (TME), limiting systemic exposure and potential ...

Additionally, mice with ovarian cancer treated with ERNA-101 exhibited ... potent pro-inflammatory factors directly to the tumor microenvironment (TME), limiting systemic exposure and potential ...

By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...

Additionally, mice with ovarian cancer treated with ERNA-101 exhibited significant survival advantage ... of MSCs to slip through the tumor's defenses and to deliver potent pro-inflammatory factors ...

By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment ... of Texas MD Anderson Cancer Center, researchers developed an ovarian tumor model by ...